Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/34180
Başlık: Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer
Yazarlar: Ulaş, Arife
Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Patoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.
0000-0003-1094-5772
0000-0002-3669-6391
0000-0002-9038-0515
0000-0002-0070-0889
0000-0001-7934-7039
0000-0002-5446-1254
0000-0002-9732-5340
Avci, Nilufer
Deligonul, Adem
Tolunay, Sahsine
Cubukcu, Erdem
Olmez, Omer Fatih
Hartavi, Mustafa
Kurt, Ender
Evrensel, Turkkan
CCT-7946-2022
ESM-4544-2022
AAI-1612-2021
ETP-1691-2022
DJG-4827-2022
CUI-5353-2022
DAS-3088-2022
AAJ-1027-2021
55390409800
37088030300
6602604390
53986153800
26435400000
55370753300
7006207332
6603942124
Anahtar kelimeler: Breast cancer
Estrogen/progesterone receptor
HER2
Immunohistochemistry
Ki-67
Neoadjuvant chemotherapy
KI67
Oncology
Yayın Tarihi: 1-Oca-2015
Yayıncı: Imprimatur Publications
Atıf: Avci, N. vd. (2015). "Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer". Journal of B.U.ON., 20(1), 45-49.
Özet: Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast cancer specimens remains controversial. We designed the current study to investigate the potential changes in estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 expression before and after NACT in a cohort of Turkish patients with breast cancer. Methods: This research was designed as a prospective, observational study of 100 consecutive patients with breast cancer (mean age 47.8 11.4 years) who were scheduled to undergo anthracycline- and/or taxane-containing NACT before attempting cytoreductive surgery at the Department of Oncology of the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded specimens. Results: Changes in immunohistochemical markers before and after NACT were only significant for HER-2 and Ki-67. More specifically, the number of HER-2-positive specimens decreased front 21 before NACT to 8 after NACT (p<0.001). Similarly, the number of tumor samples positive for Ki-67 decreased significantly from 65 to 24 after NACT (p<0.001). Mean pre- and post-treatment tumor grades of differentiation before and after NACT were 2.56 +/- 0.67 and 2.37 +/- 1.07, respectively (p<0.05). We did not find any significant associations between baseline ER, PR, HER2, and Ki-67 expression with both overall survival (OS) and disease-free survival (DFS). Conclusion: Our study suggests that NACT reduces the expression of HER2 and Ki-67 in breast cancer specimens. The significance of NACT-induced changes in the immunohistochemical expression of HER2 and Ki-67 in patients with breast cancer should be further studied in future translational and clinical research.
URI: https://doi.org/
http://hdl.handle.net/11452/34180
ISSN: 1107-0625
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.